Prostate Cancer Clinical Trials

Yes. Several trials are evaluating improved monitoring approaches for men on active surveillance, including advanced MRI techniques, blood and urine biomarkers, and genomic classifiers that better predict which cancers will remain low-risk. These trials can provide access to cutting-edge monitoring without requiring treatment.

Genetic testing is strongly recommended for all men with metastatic prostate cancer and those with high-risk localized disease or a strong family history of cancer. Results can open doors to targeted therapy trials and inform treatment decisions. Both germline (inherited) and somatic (tumor) testing should be considered.

Yes. Many prostate cancer trials enroll patients who are currently receiving androgen deprivation therapy (ADT). Some studies add investigational treatments on top of ongoing ADT, while others test new approaches for patients whose cancer has progressed despite hormone therapy. Your current treatment status helps determine which trials you qualify for.

PSMA (prostate-specific membrane antigen) is a protein found on the surface of most prostate cancer cells. PSMA-targeted therapies deliver radiation or drugs directly to cancer cells expressing this protein. Lutetium-177-PSMA-617 (Pluvicto) is the first approved radioligand therapy, and clinical trials are testing next-generation PSMA-targeted agents and combinations.

The active treatment phase ranges from a few months to two or more years, depending on the trial and disease stage. Because prostate cancer often progresses slowly, follow-up periods can be particularly long, sometimes five years or more, to assess long-term outcomes. The consent form will outline the expected time commitment.